Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. - Archive ouverte HAL Access content directly
Journal Articles British Journal of Haematology Year : 2013

Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.

(1) , (1, 2, 3)
1
2
3

Abstract

Gamma delta (γδ) Τ cells are non-conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti-tumour activity against many cancers and suggest that γδ Τ cell-mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-00802672 , version 1 (20-03-2013)

Identifiers

Cite

Mounia S. Braza, Bernard Klein. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.. British Journal of Haematology, 2013, 160 (2), pp.123-32. ⟨10.1111/bjh.12090⟩. ⟨inserm-00802672⟩
55 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More